​European Commission Grants Intercept's Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Dokument -

​European Commission Grants Intercept's Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis

  • Licens: All rights reserved
    Innehållet får bara användas av Mynewsdesk. Det är alltså inte tillåtet för någon annan att ladda ner, kopiera, sprida eller på annat sätt använda Innehållet (annat än för privat bruk i den mån det följer av lag).
  • Filformat: .pdf

Relaterat innehåll

​European Commission Grants Intercept's Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis

NEW YORK, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the European Commission has granted conditional approval for Ocaliva (obeticholic acid) for the treatment of primary biliary chola